Laurus Labs Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 26 Fair Values set on narratives written by author
LAURUSLABS Community Narratives
LAURUSLABS: Margin Pressures From Rising Input Costs Will Weigh On Earnings
Digital Transformation And Affordable Generics Will Expand Global Markets
Global Healthcare Regulation Will Squeeze Margins Amid Rising Costs
Global Healthcare Regulation Will Squeeze Margins Amid Rising Costs
View narrativeLAURUSLABS: Margin Pressures From Rising Input Costs Will Weigh On Earnings
View narrativeDigital Transformation And Affordable Generics Will Expand Global Markets
View narrativeTrending Discussion
No trending discussion available.
Recently Updated Narratives
LAURUSLABS: Rich Pricing And Lower Future P/E Will Limit Upside
LAURUSLABS: Future Returns Will Depend On Resilient Margins Supporting Elevated P E Multiples
LAURUSLABS: Higher Margin Outlook And Upcoming Results Dates Will Shape Future Appeal
Snowflake Analysis
Laurus Labs Limited Key Details
- 20.24
- 59.45%
- 15.04%
- 46.4%
About LAURUSLABS
- Founded
- 2005
- Employees
- 7059
- CEO
- Website
View website
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.